F.D.A. approves new trials for Ecstasy treating PTSD patients

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

According to The New York Times, the Food and Drug Administration gave permission for clinical trials in testing Ecstasy to treat PTSD patients on Tuesday.

The large-scale phase 3 clinical trials of the drug would be the last step in approving Ecstasy for prescription drug reasons, The New York Times said.

The drug would be used to help people suffering from Post-traumatic stress disorder.

Medical Daily says PTSD affects about 8% of Americans and that organizations around the nation are trying to help people suffering from the disorder.

Ecstasy has been outlawed and is known for its ability to make people happy or uplifted.

The New York Times also said a spokeswoman declined comment for the F.D.A. saying they can not talk about the development of drugs.